














Documents transmis le 16/03/2021 - Travoprost

| | |
|---|---|
| AMM Traglafka 40 microgrammes/ml, collyre en solution |  |
| Travoprost - Annexe 510 (2013) |  |
| Travoprost - Annexe 511 (2013) |  |
| Travoprost - Annexe 517 (2013) |  |
| Travoprost - Annexe 519 (2013) |  |
| Travoprost - Annexe 53 (2013) |  |
| Travoprost - Annexe 56 (2015) |  |
| Travoprost - Annexe 59 (2015) |  |
| Travoprost - Braille (2013) |  |
| Travoprost - Bridging report (2013) |  |
| Travoprost - Submission of a parallel Application Dossier(s) for Marketing Authorisation of Travoprost 40 micrograms/ml preservative free eye drops, solution in multi dose container with procedure number DK/H/2599/001/DC (2015) |  |
| Travoprost - History of e-CTD sequences (octobre 2015) |  |
| Travoprost - Declaration (2013) |  |

Travoprost - Package leaflet: Information for the user (2013)



Travoprost - Justification for Absence of Environmental Risk Assessment (2013)



Travoprost - Labelling (2013)



Travoprost - Certificate of GMP compliance of a manufacturer (2013)



Travoprost - Certificate of GMP compliance of a manufacturer (2013)



Travoprost - Information for generic, "hybrid" or bio-similar applications (2013)



Travoprost - Notice to applicants (2013)



Travoprost - Letter of authorisation for employees (octobre 2015)



Travoprost - Risk management plan (2013)



Travoprost - Pharmacovigilance (2013)



Travoprost - Summary of product characteristics (2013)



Travoprost - Introduction (2013)



Travoprost - Appendices (2013)



Travoprost - Clinical summary (2013)



Travoprost - Quality overall summary (2013)



Travoprost - Regional information/for UE (2013)



Travoprost - Nonclinical summary (2013)



Travoprost - List of literature references (modul 4)



